Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (416)	9/19/2002 9:48:23 AM
From: scaram(o)uche	Respond to of 496

Guilford Pharmaceuticals Announces Webcast to Discuss Phase III Long Term Survival Results of GLIADEL Wafer Thursday September 19, 9:43 am ET BALTIMORE, Md.--(BUSINESS WIRE)--Sept. 19, 2002--Guilford Pharmaceuticals (NASDAQ: GLFD - News), will host a conference call and webcast to discuss long term survival results in a Phase III clinical trial of GLIADEL® Wafer, a proprietary treatment for brain cancer. The conference call will take place at 1:00 p.m. Eastern Time on Thursday, September 19, 2002. The dial in number for U.S. residents is (888) 425-2604, and international residents, (706) 679-8253. This call is being webcast by CCBN and can be accessed at Guilford's web site at www.guilfordpharm.com, under investors/presentations. The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com). About Guilford Pharmaceuticals Guilford Pharmaceuticals Inc. is a fully integrated pharmaceutical company that discovers, develops and markets novel pharmaceutical products targeting the hospital and neurological markets. -------------------------------------------------------------------------------- Contact: Guilford Pharmaceuticals Inc. Stacey Jurchison jurchisons@guilfordpharm.com